{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"DMAC","limit":50},"count":50,"signals":[{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026; |  | |  |  (3) |  To approve, on an advisory(non-binding)basis, the compensation paid to our named executive officers; |  | |  |  (4) |  To approve the amendment and restatement of the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available for issuanc","filed_date":"2026-04-01","accession":"0001437749-26-010879","full_text":"https://origin.rootz.global/static/filing/0001437749-26-010879.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":39,"context":"hysician collaborators to conduct the study, and our expectations related to the timing of Part 1b and Parts 2 and 3 of this study; |  | |  |  |  our ability to meet anticipated site activations, enrollment and interim analysis timing with respect to our Phase 2/3 ReMEDy2 clinical trial of DM199 for the treatment of AIS, especially in the light of slower than expected site activations and enrollment","filed_date":"2026-03-30","accession":"0001437749-26-010342","full_text":"https://origin.rootz.global/static/filing/0001437749-26-010342.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":70,"context":"we choose to develop may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if granted. |  | |  |  |  We face the risk of product liability claims and may be unable to maintain product liability insurance sufficient to cover such claims or as r","filed_date":"2026-03-30","accession":"0001437749-26-010342","full_text":"https://origin.rootz.global/static/filing/0001437749-26-010342.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"art 1a of this study and the ability of these physician collaborators to identify a suitable dose for use in Part 1b of this study; |  | |  |  |  our ability to meet anticipated site activations, enrollment and interim analysis timing with respect to our Phase 2/3 ReMEDy2 clinical trial of DM199 for the treatment of AIS, especially in the light of slower than expected site activations and enrollment","filed_date":"2025-11-12","accession":"0001437749-25-034469","full_text":"https://origin.rootz.global/static/filing/0001437749-25-034469.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"ht or other restriction. Listed Shares means the voting common shares, no par value, of the Company, and any other class of securities into which such shares may hereafter be reclassified or changed. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2025-07-21","accession":"0001437749-25-023048","full_text":"https://origin.rootz.global/static/filing/0001437749-25-023048.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":28,"context":"gram in this proxy statement includes the compensation of the following executive officers required to be named in the Summary Compensation Table under *Executive Compensation* and referred to as our named executive officers or NEOs: (i) Rick Pauls, our Chief Executive Officer (CEO), (ii) Lorianne Masuoka, M.D., our Chief Medical Officer (CMO); and (iii)Scott Kellen, our Chief Financial Officer (CFO). The 2024 compensat","filed_date":"2025-03-28","accession":"0001437749-25-009696","full_text":"https://origin.rootz.global/static/filing/0001437749-25-009696.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":37,"context":"ng of our DM199 product candidate for AIS and PE and meet certain anticipated or target dates with respect to our clinical studies; |  | |  |  |  our ability to meet anticipated site activations, enrollment and interim analysis timing with respect to our Phase 2/3 ReMEDy2 clinical trial of DM199 for the treatment of AIS, especially in the light of slower than expected site activations and enrollment","filed_date":"2025-03-17","accession":"0001437749-25-008018","full_text":"https://origin.rootz.global/static/filing/0001437749-25-008018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":70,"context":"we choose to develop may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if granted. |  | |  |  |  We face the risk of product liability claims and may be unable to maintain product liability insurance sufficient to cover such claims or as r","filed_date":"2025-03-17","accession":"0001437749-25-008018","full_text":"https://origin.rootz.global/static/filing/0001437749-25-008018.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"ht or other restriction. Listed Shares means the voting common shares, no par value, of the Company, and any other class of securities into which such shares may hereafter be reclassified or changed. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Money Laundering Laws shall have the meaning ascribed","filed_date":"2024-06-26","accession":"0001437749-24-021220","full_text":"https://origin.rootz.global/static/filing/0001437749-24-021220.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":33,"context":"compensation programs includes the compensation of the following executive officers required to be named in the Summary Compensation Table under Executive Compensation section and referred to as our named executive officers or NEOs: (i) Rick Pauls, our Chief Executive Officer (CEO), (ii) Scott Kellen, our Chief Financial Officer (CFO) and Julie Daves, our Senior Vice President, Clinical Development Operations (SVP, Cli","filed_date":"2024-04-04","accession":"0001437749-24-010985","full_text":"https://origin.rootz.global/static/filing/0001437749-24-010985.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":34,"context":"get dates with respect to our clinical studies, including in particular our Phase 2/3 ReMEDy2 clinical trial of DM199 for the treatment of AIS, or ReMEDy2 trial, and anticipated site activations, enrollment and interim analysis timing, especially in the light of the effects of COVID-19, particularly on hospital and medical facility staffing shortages, concerns managing logistics and protocol complian","filed_date":"2024-03-19","accession":"0001437749-24-008522","full_text":"https://origin.rootz.global/static/filing/0001437749-24-008522.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":55,"context":"ommittees for re-examination, which may impact the cost, timing or successful completion of our ReMEDy2 trial. Delays or increased product development costs or any of these events would likely have a material adverse effect on our business, financial condition, and prospects. **The COVID-19 pandemic adversely impacted hospital and medical facilities, causing, among other things, staffing shortages, which have previously","filed_date":"2024-03-19","accession":"0001437749-24-008522","full_text":"https://origin.rootz.global/static/filing/0001437749-24-008522.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"199 product candidate for AIS or CRD and meet certain anticipated or target dates with respect to our clinical studies, including in particular our ReMEDy2 trial and anticipated site activations, enrollment and interim analysis timing, especially in the light of COVID-19, hospital and medical facility staffing shortages, concerns managing logistics and protocol compliance for participants discharged","filed_date":"2023-11-13","accession":"0001437749-23-031671","full_text":"https://origin.rootz.global/static/filing/0001437749-23-031671.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"ith respect to our clinical studies, including in particular our ReMEDy2 trial and especially in the light of the effects of novel strains of the coronavirus, or COVID-19, on site activations and enrollment, hospital and medical facility staffing shortages, and concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility; |  | &#xa","filed_date":"2023-08-14","accession":"0001437749-23-023708","full_text":"https://origin.rootz.global/static/filing/0001437749-23-023708.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":30,"context":"ht or other restriction. Listed Shares means the voting common shares, no par value, of the Company, and any other class of securities into which such shares may hereafter be reclassified or changed. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Person means an individual or corporation, partnership","filed_date":"2023-06-21","accession":"0001437749-23-017922","full_text":"https://origin.rootz.global/static/filing/0001437749-23-017922.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"ith respect to our clinical studies, including in particular our ReMEDy2 trial and especially in the light of the effects of novel strains of the coronavirus, or COVID-19, on site activations and enrollment, hospital and medical facility staffing shortages, and concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility, and the c","filed_date":"2023-05-15","accession":"0001437749-23-014616","full_text":"https://origin.rootz.global/static/filing/0001437749-23-014616.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":27,"context":"he 2023 Annual General and Special Meeting of Shareholders for a one-year term. All director nominees listed below served during the fiscal year ended December 31, 2022, except for Ms. Lewis, who was appointed to the Board of Directors effective as of March 1, 2023. |  Director |  Age |  Serving Since |  Independent |  | |  Michael Giuffre, M.D. |  67 |  2010 |  Yes |  | |  Tanya Lewis |  52 |  2023 |  Yes |  | |  James Parsons |","filed_date":"2023-04-04","accession":"0001437749-23-009169","full_text":"https://origin.rootz.global/static/filing/0001437749-23-009169.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":57,"context":"ith respect to our clinical studies, including in particular our ReMEDy2 trial and especially in the light of the effects of novel strains of the coronavirus, or COVID-19, on site activations and enrollment, hospital and medical facility staffing shortages, and concerns managing logistics and protocol compliance for participants discharged from the hospital to an intermediate care facility, and the c","filed_date":"2023-03-28","accession":"0001437749-23-008189","full_text":"https://origin.rootz.global/static/filing/0001437749-23-008189.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"ommittees for re-examination, which may impact the cost, timing or successful completion of our ReMEDy2 trial. Delays or increased product development costs or any of these events would likely have a material adverse effect on our business, financial condition, and prospects. &#xa0; 36 &#xa0; &#xa0; **The COVID-19 pandemic resulted in delays in clinical trial site activations and patient enrollments and hospital and med","filed_date":"2023-03-28","accession":"0001437749-23-008189","full_text":"https://origin.rootz.global/static/filing/0001437749-23-008189.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":24,"context":"CKD and meet certain anticipated or target dates with respect to our clinical studies, including in particular our ReMEDy2 trial and especially in the light of the effects on site activations and enrollment of novel strains of the coronavirus, or COVID-19, hospital and medical facility staffing shortages, and concerns managing logistics and protocol compliance for patients discharged from the hospita","filed_date":"2022-11-09","accession":"0001437749-22-026609","full_text":"https://origin.rootz.global/static/filing/0001437749-22-026609.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":25,"context":"|  | |  &#xa0; |  &#x25cf; |  our ability to conduct successful clinical testing of our DM199 product candidate for AIS and CKD and meet certain anticipated or target dates, site activations and enrollment numbers with respect to our clinical studies, especially in the light of the effects of novel strains of the coronavirus, or COVID-19, hospital and medical facility staffing shortages and concerns","filed_date":"2022-08-11","accession":"0001437749-22-019848","full_text":"https://origin.rootz.global/static/filing/0001437749-22-019848.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":24,"context":"sary of the first Lease Year. The first Lease Year shall include any initial partial calendar month. 1.14 **Base Rent:** Base Rent shall be as follows: |  Months |  |  |  Per SF |  |  |  Monthly Installment |  |  |  Base Rent for Period |  |  | |  01 12 |  |  |  $ |  17.00 |  |  |  $ |  8,747.92 |  |  |  $ |  104,975.00 |  |  | |  13 24 |  |  |  $ |  17.51 |  |  |  $ |  9,010.35 |  |  |  $ |  108,124","filed_date":"2022-06-29","accession":"0001437749-22-016176","full_text":"https://origin.rootz.global/static/filing/0001437749-22-016176.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"date; |  | |  &#xa0; |  &#x25cf; |  our ability to conduct successful clinical testing of our DM199 product candidate for AIS and CKD and certain anticipated or target dates, site activations and enrollment numbers with respect to our clinical studies, especially in the light of the novel strain of coronavirus, or COVID-19 pandemic on site activations and enrollment, and the effect of hospital and me","filed_date":"2022-05-04","accession":"0001437749-22-010876","full_text":"https://origin.rootz.global/static/filing/0001437749-22-010876.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":28,"context":"apeutics, and Dr. Charles Semba, Chief Medical Officer of Eluminex Biosciences, to our Board. Ms. Burroughs and Dr Semba together have more than 40 years of industry experience. |  | |  |  |  |  | |  Appointed Chief Medical Officer |  |  In January 2022, we announced the appointment of Kirsten Gruis, M.D. as Chief Medical Officer. Dr. Gruis is a board-certified neurologist with 20 years of experience in both clinical medicine a","filed_date":"2022-04-05","accession":"0001437749-22-008264","full_text":"https://origin.rootz.global/static/filing/0001437749-22-008264.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":41,"context":"date; |  | |  &#xa0; |  &#x25cf; |  our ability to conduct successful clinical testing of our DM199 product candidate for AIS and CKD and certain anticipated or target dates, site activations and enrollment numbers with respect to our clinical studies, especially in the light of the novel strain of coronavirus, or COVID-19 pandemic on site activations and enrollment, hospital and medical facility sta","filed_date":"2022-03-14","accession":"0001437749-22-006163","full_text":"https://origin.rootz.global/static/filing/0001437749-22-006163.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":19,"context":"ethics committees for re-examination, which may impact the cost, timing or successful completion of any current or future trial. Delays or increase product development costs, any of which may have a material adverse effect on our business, financial condition, and prospects. &#xa0; **The COVID-19 pandemic has resulted in delays in clinical trial site activations and patient enrollments and hospital and medical facility","filed_date":"2022-03-14","accession":"0001437749-22-006163","full_text":"https://origin.rootz.global/static/filing/0001437749-22-006163.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"| &#xa0; |  &#xa0; |  &#x25cf; |  our ability to conduct successful clinical testing of our DM199 product candidate for AIS and CKD and certain anticipated or target dates, site activations and enrollment numbers with respect to our pending and anticipated clinical studies, especially in light of the impact of the novel strain of coronavirus, or COVID-19, pandemic, on site activations and enrollmen","filed_date":"2021-11-10","accession":"0001437749-21-026175","full_text":"https://origin.rootz.global/static/filing/0001437749-21-026175.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":29,"context":"Date shall have the meaning ascribed to such term in Section 4.1(d). Liens means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction. Material Adverse Effect shall have the meaning assigned to such term in Section 3.1(b). Material Permits shall have the meaning ascribed to such term in Section 3.1(n). Person means an individual or corporation, partnership","filed_date":"2021-09-27","accession":"0001437749-21-022654","full_text":"https://origin.rootz.global/static/filing/0001437749-21-022654.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"|  2020 EXECUTIVE COMPENSATION ACTIONS |  | 2020 compensation actions and incentive plan outcomes based on performance are summarized below: |  Element |  Key 2020 Actions |  | |  Base Salary |  Our named executive officers received increases of 3% over their respective 2019 base salaries. |  | |  Short-Term Incentive |  Our named executive officers received short-term incentive cash payments equal to 95% of their resp","filed_date":"2021-06-03","accession":"0001437749-21-014066","full_text":"https://origin.rootz.global/static/filing/0001437749-21-014066.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":25,"context":"o, Canada. 3 We believe that Mr. Parsons financial experience, including his history and knowledge of our company, enable him to make valuable contributions to the Board of Directors. *Rick Pauls*was appointed our President and Chief Executive Officer in January 2010. Mr. Pauls has served as a member of the Board of Directors since April 2005 and the Chairman of the Board from April 2008 to July 2014. Prior to joining DiaMedica,","filed_date":"2021-04-29","accession":"0001437749-21-010229","full_text":"https://origin.rootz.global/static/filing/0001437749-21-010229.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":25,"context":"rolling |  Primary endpoint at day 95: Safety & tolerability Proteinuria and eGFR Secondary endpoints at day 90: Change in blood pressure |  | |  Diabetic Kidney Disease (DKD) |  SC |  Phase 2 |  Enrollment complete |  Primary endpoint at day 95: Safety & tolerability Proteinuria and eGFR Secondary endpoints at day 90: Change in blood sugar levels |  | **Supporting Data for Use of DM199 (KLK1):** We","filed_date":"2021-03-10","accession":"0001437749-21-005541","full_text":"https://origin.rootz.global/static/filing/0001437749-21-005541.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"ulatory authorities or IRBs or ethics committees for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development costs may have a material adverse effect on our business, financial condition, and prospects. **The COVID-19 pandemic has resulted in a delay in enrollment in our REDUX trial and will likely continue to result in enrollment delays and could","filed_date":"2021-03-10","accession":"0001437749-21-005541","full_text":"https://origin.rootz.global/static/filing/0001437749-21-005541.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":27,"context":"to five years, if at all. Additionally, clinical testing is currently being adversely impacted by the novel strain of the coronavirus (COVID-19) pandemic. We are experiencing slower than expected enrollment in the REDUX clinical trial due to the reduction or suspension of activities at our clinical study sites as they address staff and patient safety concerns and patient concerns related to visiting","filed_date":"2020-11-04","accession":"0001437749-20-022537","full_text":"https://origin.rootz.global/static/filing/0001437749-20-022537.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"to five years, if at all. Additionally, clinical testing is currently being adversely impacted by the novel strain of the coronavirus (COVID-19) pandemic. We are experiencing slower than expected enrollment in the REDUX clinical trial due to the reduction or suspension of activities at our clinical study sites as they address staff and patient safety concerns and patient concerns related to visiting","filed_date":"2020-08-11","accession":"0001437749-20-017514","full_text":"https://origin.rootz.global/static/filing/0001437749-20-017514.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":15,"context":"d standing in each jurisdiction in which it owns or leases real property or in which the conduct of its business makes such qualification necessary and in which the failure to so qualify would have a material adverse effect upon the business, prospects, management, properties, operations, condition (financial or otherwise) or results of operations of the Company and its Subsidiaries, taken as a whole (**Material Adverse","filed_date":"2020-08-07","accession":"0001437749-20-017105","full_text":"https://origin.rootz.global/static/filing/0001437749-20-017105.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":27,"context":"* ** **2019 EXECUTIVE COMPENSATION ACTIONS** 2019 compensation actions and incentive plan outcomes based on performance are summarized below: |  Element |  Key 2019 Actions |  | |  Base Salary |  Our named executive officers received increases between 13% and 29% over their respective 2018 base salaries to bring them closer to our target market positioning. |  | |  Short-Term Incentive |  Our named executive officers re","filed_date":"2020-04-20","accession":"0001437749-20-007997","full_text":"https://origin.rootz.global/static/filing/0001437749-20-007997.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":24,"context":"oints include safety, tolerability, blood pressure, albuminuria and kidney function, which will be evaluated by changes from baseline in eGFR and albuminuria, as measured by the UACR. Participant enrollment and dosing for this study commenced in December 2019. **AIS Phase II REMEDY Study** In February 2018, treatment was initiated for the first patient in our Phase II REMEDY trial assessing the safet","filed_date":"2020-03-23","accession":"0001437749-20-005906","full_text":"https://origin.rootz.global/static/filing/0001437749-20-005906.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"ulatory authorities or IRBs or ethics committees for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development costs may have a material adverse effect on our business, financial condition, and prospects. ***Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and unc","filed_date":"2020-03-23","accession":"0001437749-20-005906","full_text":"https://origin.rootz.global/static/filing/0001437749-20-005906.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ca Therapeutics****Annou****n****ces 201****9****Financial****Result****s and****Provides****Business****Update** ** *** |  |  |  REMEDY Phase II Study of DM199 in Acute Ischemic Stroke Completes Enrollment; Data Readout Expected in Q2 2020 |  | |  |  |  Phase II Study of DM199 in Chronic Kidney Disease Ongoing; Steps Being Taken to Mitigate Potential Impact of COVID-19 |  | |  |  |  Raised $8.5 Mill","filed_date":"2020-03-23","accession":"0001437749-20-005905","full_text":"https://origin.rootz.global/static/filing/0001437749-20-005905.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":28,"context":"ulatory authorities or IRBs or ethics committees for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development costs may have a material adverse effect on our business, financial condition, and prospects. **Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and unce","filed_date":"2020-02-11","accession":"0001437749-20-002240","full_text":"https://origin.rootz.global/static/filing/0001437749-20-002240.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":27,"context":"io, Canada. We believe that Mr. Parsons financial experience, including his history and knowledge of our company, enable him to make valuable contributions to the Board of Directors. *Rick Pauls* was appointed our President and Chief Executive Officer in January 2010. Mr. Pauls has served as a member of the Board of Directors since April 2005 and the Chairman of the Board from April 2008 to July 2014. Prior to joining DiaMedica,","filed_date":"2019-04-08","accession":"0001437749-19-006692","full_text":"https://origin.rootz.global/static/filing/0001437749-19-006692.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"ulatory authorities or IRBs or ethics committees for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development costs may have a material adverse effect on our business, financial condition, and prospects. 32 * * **Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming a","filed_date":"2019-03-19","accession":"0001437749-19-005272","full_text":"https://origin.rootz.global/static/filing/0001437749-19-005272.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"ulatory authorities or IRBs or ethics committees for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development costs may have a material adverse effect on our business, financial condition, and prospects. **Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and unce","filed_date":"2018-11-28","accession":"0001437749-18-021321","full_text":"https://origin.rootz.global/static/filing/0001437749-18-021321.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"nt history of each of our executive officers and directors are set forth below. Pursuant to the CBCA, at least 25% of our directors must be resident Canadians. **Executive Officers** *Rick Pauls* was appointed our President and Chief Executive Officer in January 2010. Mr. Pauls has served as a member of our Board of Directors since April 2005 and the Chairman of the Board from April 2008 to July 2014. Prior to joining DiaMedica,","filed_date":"2018-11-28","accession":"0001437749-18-021321","full_text":"https://origin.rootz.global/static/filing/0001437749-18-021321.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":26,"context":"ulatory authorities or IRBs or ethics committees for re-examination, which may impact the cost, timing or successful completion of that trial. Delays or increased product development costs may have a material adverse effect on our business, financial condition, and prospects. **Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time-consuming and unce","filed_date":"2018-11-09","accession":"0001437749-18-020300","full_text":"https://origin.rootz.global/static/filing/0001437749-18-020300.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"nt history of each of our executive officers and directors are set forth below. Pursuant to the CBCA, at least 25% of our directors must be resident Canadians. **Executive Officers** *Rick Pauls* was appointed our President and Chief Executive Officer in January 2010. Mr. Pauls has served as a member of our Board of Directors since April 2005 and the Chairman of the Board from April 2008 to July 2014. Prior to joining DiaMedica,","filed_date":"2018-11-09","accession":"0001437749-18-020300","full_text":"https://origin.rootz.global/static/filing/0001437749-18-020300.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"hysician collaborators to conduct the study, and our expectations related to the timing of Part 1b and Parts 2 and 3 of this study; |  | |  |  |  our ability to meet anticipated site activations, enrollment and interim analysis timing with respect to our Phase 2/3 ReMEDy2 clinical trial of DM199 for the treatment of AIS, especially in the light of slower than expected site activations and enrollment","filed_date":"2026-08-10","accession":"0001437749-26-026792","full_text":"https://origin.rootz.global/static/filing/0001437749-26-026792.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":98,"match_count":11,"context":"d standing in each jurisdiction in which it owns or leases real property or in which the conduct of its business makes such qualification necessary and in which the failure to so qualify would have a material adverse effect upon the business, prospects, management, properties, operations, condition (financial or otherwise) or results of operations of the Company and its subsidiaries, taken as a whole (***Material Advers","filed_date":"2020-02-13","accession":"0001437749-20-002598","full_text":"https://origin.rootz.global/static/filing/0001437749-20-002598.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"art 1A of this study and the ability of these physician collaborators to identify a suitable dose for use in Part 1B of this study; |  | |  |  |  our ability to meet anticipated site activations, enrollment and interim analysis timing with respect to our Phase 2/3 ReMEDy2 clinical trial of DM199 for the treatment of AIS, especially in the light of slower than expected site activations and enrollment","filed_date":"2025-05-13","accession":"0001437749-25-016488","full_text":"https://origin.rootz.global/static/filing/0001437749-25-016488.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"DMAC","company":"DiaMedica Therapeutics Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"****linical Developments** ***DM199 for the Treatment of Chronic Kidney Disease *** *Phase II Clinical Study in**CKD Caused by**IgA Nephropathy**,****in**African Americans with Hypertension****** Enrollment Continues* *Initiation of Third Cohort in CKD caused by Type II Diabetes Mellitus* The Phase II REDUX (latin for restore) trial is a multi-center, open-label investigation of approximately 90 eval","filed_date":"2020-08-11","accession":"0001437749-20-017512","full_text":"https://origin.rootz.global/static/filing/0001437749-20-017512.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"efb8b7afba7724e6d565b71c0ce401f581bc742431e3fe3ddf20ee8a137bc3fb","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"f179b16ff74e45364c95c38bb90c59a4a1887918ad420e47413162bd03dc95a9","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":2,"hourly_limit":500,"remaining":498,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}